에이프로젠

007460KOSPI

64.8 / 100

Reference Date: 2026-09-09

Financial Score19.5 / 40

News Sentiment21.3 / 25

Momentum9.0 / 20

Disclosure15.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Plunged 16.5% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Aprogen operates major businesses in hardfacing, steel sales, nuclear insulation, pharmaceuticals, and biopharmaceuticals, maintaining a leading position in the domestic hardfacing market. The biopharmaceutical division focuses on developing biosimilars and new drugs, successfully selling Remicade biosimilars in the Japanese market.

Number of Employees

311people

Average Salary

52.0M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

0.11Industry Average 1.207.0Point

Half of industry avg (excellent)

ROE

-31.28Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

16.33Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20250.5 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼10.9% (2-year basis)

Operating Profit Growth Rate

0.5 / 3

Avg ▼3.9% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -25.6% (declining, 3yr)

Detailed News Sentiment

6 totalPositive 6Neutral 0Negative 0Average Sentiment Score 85

Positive
앱튼, GPC-100 美 임상 3상 착수…식품의약국 품목허가 추진
앱튼의 GPC-100 임상 3상 시작으로 에이프로젠 자회사의 신약 개발 진전이 기대되어 긍정적 영향.
Positive
앱튼, FDA 희귀의약품 'GPC-100' 美 3상 착수… 13조 다...
앱튼의 혈액암 신약 GPC-100의 미국 임상 3상 시작으로 에이프로젠 자회사의 기술적 성과와 시장 경쟁력 강화가 기대된다.
Positive
[마감시황]코스피, 반도체·전력기기 강세에 6,912.37 마감…외국인...
에이프로젠을 포함한 반도체 및 전력기기 관련 종목 강세로 코스피가 상승했다.

Detailed Momentum

52-week position3.0Point

52w lower range (28%)

Current 2,120Won52-week high 6,76052-week low 280

1-month return0.0Point

1m -16.54% (strong drop)

Volume trend6.0Point

Volume surge

Detailed Disclosure

7 totalPositive 3Neutral 4Negative 0

Positive주요사항보고서(유상증자결정)(자회사의 주요경영사항)2026-09-03
Neutral주요사항보고서(전환사채권발행결정)2026-09-03
Neutral주식등의대량보유상황보고서(일반)2026-08-28
Neutral주식등의대량보유상황보고서(일반)2026-08-21
Positive유상증자또는주식관련사채등의발행결과(자율공시)2026-08-21